|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Equity method investments | ||||||||||||||||||||
| Receivables, net of allowance of $56 million and $62 million, respectively ($1.0 billion and $629 million from equity method investees, respectively) | ||||||||||||||||||||
| Commercial receivables | ||||||||||||||||||||
| Government receivables | ||||||||||||||||||||
| Total receivables, net of allowance of $56 million and $62 million, respectively ($1.0 billion and $629 million from equity method investees, respectively) | ||||||||||||||||||||
| Receivables held-for-sale | ||||||||||||||||||||
| Real estate | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Receivables held-for-sale (includes $51 million under fair value option as of June 30, 2026) | ||||||||||||||||||||
| Real estate and available-for-sale debt securities | ||||||||||||||||||||
| Retained interests in securitization trusts, net of allowance of $3 million and $3 million, respectively | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Accounts payable, accrued expenses and other | ||||||||||||||||||||
| Credit facilities | ||||||||||||||||||||
| Commercial paper notes | ||||||||||||||||||||
| Term loans payable | ||||||||||||||||||||
| Non-recourse debt (secured by assets of $302 million and $311 million, respectively) | ||||||||||||||||||||
| Senior unsecured notes | ||||||||||||||||||||
| Senior notes | ||||||||||||||||||||
| Junior subordinated notes | ||||||||||||||||||||
| Convertible notes | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Preferred stock, par value $0.01 per share, 50,000,000 shares authorized, no shares issued and outstanding | ||||||||||||||||||||
| Common stock, par value $0.01 per share, 450,000,000 shares authorized, 127,945,053 and 127,644,496 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
Loading...
